miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway

Jihye Kim; Jinmai Jiang; Mohamed Badawi; Thomas D Schmittgen

doi:10.1016/j.bbrc.2017.04.121

Related publications

Article2024

Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway

Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Lixia Sheng, Guifang Ouyang

Current Molecular Medicine

Article2011

miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival

Jong Kook Park, Takayuki Kogure, Gerard J. Nuovo, Jinmai Jiang, Lei He, Ji Hye Kim, Mitch A. Phelps, Tracey L. Papenfuss, Carlo M. Croce, Tushar Patel, Thomas D Schmittgen

Article2021

Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration

Sajad Fakhri, Amin Iranpanah, Mohammad Mehdi Gravandi, Seyed Zachariah Moradi, Mohammad Ranjbarı, Mohammad Bagher Majnooni, Javier Echeverría, Yaping Qi, Mingfu Wang, Pan Liao, Mohammad Hosein Farzaei, Jianbo Xiao

Article2020

Aluminum-Induced Cognitive Impairment and PI3K/Akt/mTOR Signaling Pathway Involvement in Occupational Aluminum Workers

Nan Shang, Ping Zhang, Shuo Wang, Jianping Chen, Rong Fan, Chen Jin, Tao Huang, Yan‐Hong Wang, Jeremy W. Duncan, Ling Zhang, Q. L. Niu, Qinli Zhang

Neurotoxicity Research

Article2010

miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines

David M. Nagorney, Lewis R. Roberts, Soma Banerjee, Thomas D Schmittgen, Jon C. Henry, Jong Kook Park, Jinmai Jiang, Ji Hye Kim